Multiple Myeloma | Topics

 
Kathryn Maples, PharmD, BCOP, on Key Considerations for Belantamab Mafodotin Administration in Multiple Myeloma
May 13, 2021

A clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma.

Kathryn Maples, PharmD, BCOP, on the REMS Program for Belantamab Mafodotin
May 10, 2021

A clinical pharmacy specialist details her experience with the REMS program for administration of belantamab mafodotin in patients with multiple myeloma.

Motixafortide Reaches Primary End Point of Improved Stem Cell Mobilization in Multiple Myeloma Trial
May 05, 2021

Statistical significance was reached across all end points of the phase 3 GENESIS trial investigating granulocyte colony stimulating factor plus either motixafortide or placebo in patients with multiple myeloma receiving autologous bone marrow transplantation.